Health technology assessment under scrutiny.

The article discusses the management of expensive treatments by healthcare technology assessment (HTA), a multidisciplinary field of policy analysis. As stated, Great Britain's HTA the National Institute for Health and Clinical Excellence has caused frustration to the pharmaceutical industry in not recommending payment for Novartis multiple sclerosis drug Gilenya. The article also provides information on accusations of several European HTAs of countries including Germany, France and Sweden.